Study of a vision test for Stargardt and geographic atrophy
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests a new way to measure vision, called MLSDT, in people with normal sight or vision loss from Stargardt disease or geographic atrophy (a type of advanced age-related macular degeneration). Results will help doctors better understand how well patients can see.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You can understand and agree to the study
- You can follow the study's testing instructions
- You have either normal vision, or vision loss from Stargardt disease or geographic atrophy (advanced macular degeneration)
- If you had anti-VEGF injections (for eye conditions), your vision must have been stable for 3 months and your eye must be fluid-free on a scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will check if certain vision tests work well in people with retinal diseases like retinitis pigmentosa or Stargardt. Results will help design future trials.
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
This study observes how Stargardt disease and similar eye conditions change over time in children and adults. It aims to learn more about the disease progression to help develop future treatments.
This study uses specialized eye imaging to track changes in geographic atrophy, a type of vision loss from macular degeneration. Researchers will use new imaging techniques to better understand how this condition progresses and how treatments work.
This study uses special eye imaging to look closely at areas of damage in the back of the eye (geographic atrophy) caused by age-related macular degeneration. It will help doctors understand early-stage disease better and may guide future treatments.
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.